Isozyme specific drug oxidation: Genetic polymorphism and drug-drug interactions
- 1 January 1993
- journal article
- research article
- Published by Taylor & Francis in Nordic Journal of Psychiatry
- Vol. 47 (sup30) , 21-26
- https://doi.org/10.3109/08039489309104121
Abstract
Cytochrome P450 denotes a group of heme proteins which catalyse the oxidation of numerous drugs and other chemicals. For six drug-metabolizing P450s one or more drugs as substrate have been identified. Variability in elimination and drug-drug interactions can be predicted if the overall metabolism of a drug can be assigned to a single well-characterized P450.Keywords
This publication has 23 references indexed in Scilit:
- Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamilyBiochemistry, 1991
- The P450 Superfamily: Update on New Sequences, Gene Mapping, and Recommended NomenclatureDNA and Cell Biology, 1991
- Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populationsEuropean Journal of Clinical Pharmacology, 1990
- Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplificationThe Lancet, 1990
- Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines.Proceedings of the National Academy of Sciences, 1989
- Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in manBiochemistry, 1988
- Sparteine Oxidation Polymorphism in DenmarkActa Pharmacologica et Toxicologica, 1985
- Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in manEuropean Journal of Clinical Pharmacology, 1984
- Defective N-oxidation of sparteine in man: A new pharmacogenetic defectEuropean Journal of Clinical Pharmacology, 1979
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977